title: Virologic outcome after switching from a nucleoside reverse transcriptase inhibitor to tenofovir in patients with undetectable HIV-1 RNA plasma level.
authors.forename: Marc
authors.initials: M
authors.lastname: Wirden
authors.forename: Anne Geneviève
authors.initials: AG
authors.lastname: Marcelin
authors.forename: Roland
authors.initials: R
authors.lastname: Tubiana
authors.forename: Marc Antoine
authors.initials: MA
authors.lastname: Valantin
authors.forename: Jade
authors.initials: J
authors.lastname: Ghosn
authors.forename: Claudine
authors.initials: C
authors.lastname: Duvivier
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Dominguez
authors.forename: Luc
authors.initials: L
authors.lastname: Paris
authors.forename: Rachid
authors.initials: R
authors.lastname: Agher
authors.forename: Gilles
authors.initials: G
authors.lastname: Peytavin
authors.forename: Christine
authors.initials: C
authors.lastname: Katlama
authors.forename: Vincent
authors.initials: V
authors.lastname: Calvez
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects / Q000302:isolation & purification; D006801:Humans; D063065:Organophosphonates / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood*; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D000068698:Tenofovir; D016896:Treatment Outcome; D014766:Viremia / Q000188:drug therapy / Q000821:virology
chemical_list: D019380:Anti-HIV Agents; D063065:Organophosphonates; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D000225:Adenine